prismmarketview
Oct 14, 2:14 PM
Arrowhead
$ARWR reported interim Phase 1/2a data showing its subcutaneous siRNA, ARO-MAPT, cut spinal fluid tau in healthy volunteers by a mean of 73% at the highest dose, with reductions holding 90 days after the last injection.
The delivery race is now in the clinic. Denali
$DNLI expects biomarker data from its IV-delivered tau-lowering ASO in 1H 2027. Voyager
$VYGR plans to begin dosing its one-time IV tau-silencing gene therapy this quarter. Annovis
$ANVS expects topline Phase 3 data for its daily oral pill in March 2027.
https://prismmarketview.com/arrowheads-under-the-skin-tau-data-puts-brain-delivery-in-focus-for-alzheimers-stocks/
